Filing Flows › GoodRx Holdings (GDRX) › Q1 2026 › vs Q4 2025
GoodRx Holdings (GDRX) Q1 2026 vs Q4 2025 (quarter over quarter)
GoodRx Holdings's revenue fell $779K (-0.4%) from $195M in Q4 2025 to $194M in Q1 2026. Operating margin 7.2% against 11.6% (-4.4 pts).
GoodRx Holdings, Q1 2026: revenue $194M (-4% year over year), operating margin 7.2%, net earnings $1.2M, operating cash flow $11.8M. The chart draws each line against Q4 2025, the increases inside each band.
Margins
| Q1 2026 | Q4 2025 | Change | |
|---|---|---|---|
| Operating margin | 7.2% | 11.6% | -4.4 pts |
| Net margin | 0.6% | 2.8% | -2.2 pts |
| Free cash flow margin | 5.5% | 16.2% | -10.7 pts |
Every line
| Line | Q1 2026 | Q4 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $194M | $195M | −$779K | -0.4% |
| Operating profit | $14.0M | $22.7M | −$8.7M | -38% |
| Costs & expenses | $180M | $172M | $7.9M | +5% |
| Pre-tax earnings | $5.6M | $14.2M | −$8.6M | -60% |
| Other expense, net | $8.4M | $8.5M | −$120K | -1% |
| Cost of revenue | $20.2M | $17.5M | $2.7M | +15% |
| Research & development | $30.2M | $28.9M | $1.2M | +4% |
| Sales & marketing | $81.1M | $78.6M | $2.4M | +3% |
| General & admin | $26.8M | $23.9M | $2.9M | +12% |
| Other operating costs | $21.8M | $23.1M | −$1.4M | -6% |
| Net earnings | $1.2M | $5.4M | −$4.3M | -78% |
| Income tax | $4.5M | $8.8M | −$4.3M | -49% |
| Operating cash sources | $39.5M | $46.5M | −$7.0M | -15% |
| Depreciation & amortization | $21.8M | $23.1M | −$1.4M | -6% |
| Share-based compensation | $16.5M | $17.9M | −$1.4M | -8% |
| Working capital & other | $27.6M | $13.6M | $14.0M | +103% |
| Operating cash flow | $11.8M | $32.9M | −$21.1M | -64% |
| Free cash flow (OCF − capex) | $10.7M | $31.6M | −$20.9M | -66% |
| Capital expenditures | $1.1M | $1.2M | −$105K | -8% |
Questions
How much did GoodRx Holdings's revenue grow quarter over quarter in Q1 2026?
GoodRx Holdings's revenue fell $779K (-0.4%) from $195M in Q4 2025 to $194M in Q1 2026. Operating margin 7.2% against 11.6% (-4.4 pts).